Possis Medical AngioJet XMI-RX
This article was originally published in The Gray Sheet
Executive Summary
Rapid-exchange version of the firm's XMI Rheolytic thrombectomy catheter is approved via PMA supplement for coronary use with the firm's AngioJet system. Previously approved for peripheral use, XMI-RX also has received a CE mark for coronary use in Europe, clearing the way for its launch at the Paris Course on Revascularization meeting May 25-28. The firm expects the catheter to boost AngioJet market penetration (1"The Gray Sheet" Feb. 23, 2004, p. 21)...
You may also be interested in...
AngioJet Thrombectomy System Aids Cost Saving In DES Procedures – Possis
The advent of drug-eluting stents (DES) is benefiting sales of Possis Medical's AngioJet Rheolytic thrombectomy system, the firm says
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.